Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
1(9%)
Results Posted
100%(6 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_3
7
64%
Ph phase_1
3
27%
Ph phase_2
1
9%

Phase Distribution

3

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
7(63.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(6)
Terminated(4)

Detailed Status

Completed6
Terminated4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (27.3%)
Phase 21 (9.1%)
Phase 37 (63.6%)

Trials by Status

terminated436%
active_not_recruiting19%
completed655%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT04273945Phase 3

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

Active Not Recruiting
NCT03904693Phase 3

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Completed
NCT04540744Phase 1

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

Completed
NCT03153137Phase 3

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

Completed
NCT05236231Phase 1

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

Completed
NCT03714815Phase 2

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Terminated
NCT01474122Phase 3

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

Terminated
NCT02050802Phase 1

Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects

Completed
NCT03775421Phase 3

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

Terminated
NCT03809650Phase 3

A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Terminated
NCT01743001Phase 3

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11